The presnt study by  Calvo  A M and colleagues assessed the possible association between polymorphisms in the CYP2C8*3 and CYP2C9 genes with the therapeutic effect of oral piroxicam (20 mg daily for 4 days) after lower third molar surgeries with regard to postoperative pain, swelling, trismus, adverse reactions, need for rescue medication and the volunteer’s overall satisfaction. To achieve this CYP2C8*3 and CYP2C9 polymorphisms on  genotyped 102 volunteers and genomic DNA was isolated from collected saliva subjected to invasive lower third molar surgeries, and the data collected and analyzed from preoperative, intraoperative and postoperative parameters. An equal amount of piroxicam sufficiently managed postoperative pain and inflammatory symptoms, with visual analog pain scores typically <40 mm for all genotypes investigated resulted. Only 2 out of 102 volunteers heterozygous for CYP2C8*3 and CYP2C9*3 reported adverse side effects. In general, slow metabolizers of piroxicam, who were volunteers with mutant alleles, were indifferent from normal metabolizers with the wild-type alleles and therefore, did not require specialized piroxicam doses to manage the postoperative pain and inflammation.